

10/509096

DTOS Rec'd PCT/PTO 27 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Chise MUKAIDANI et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2004_1543A
Filed September 27, 2004 :

ANTIBODY RECOGNIZING PROLIFERATIVE
HUMAN HEPATOCYTES, PROLIFERATIVE
HUMAN HEPATOCYTES AND FUNCTIONAL
HUMAN HEPATOCYTES

[Corresponding to PCT/JP03/03624
Filed March 25, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication (*for U.S. National applications filed after June 30, 2003 and International applications that have entered U.S. National Stage after June 30, 2003*),
- ☒ each reference previously cited in the international application PCT/JP03/03624; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____

1a. ☒ This Information Disclosure Statement is submitted:

ATTACHMENT C

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

- 1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) ☐ the certification of paragraph 2 below is provided, **or**
(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

**the certification of paragraph 2 below is provided, and
the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification

10/509096

after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:

5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Chise MUKAIDANI et al.

By Warren M. Cheek, Jr.
 Warren M. Cheek, Jr.
 Registration No. 33,367
 Attorney for Applicants

WMC/dlk
 Washington, D.C. 20006-1021
 Telephone (202) 721-8200
 Facsimile (202) 721-8250
 September 27, 2004

FORM PTO 1449 (modified)

ATTY DOCKET NO.
2004_1543ASERIAL NO.
NEW

10/509096

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 27, 2004

APPLICANT
Chise MUKAIDANI et al.FILING DATE
September 27, 2004

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AJ	00/03001	1/2000	WO			
	AK	00/43498	7/2000	WO			
	AL	61-189299	8/1986	JP			
	AM	682106	5/1996	EP			
	AN						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

AO	R. Jover et al., "Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting", Hepatology, Vol. 33, No. 3, pp. 668-675, 2001.
AP	D. Stroup et al., "HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7 alpha-hydroxylase gene (CYP7A1)", J. Lipid Res., Vol. 41, No. 1, pp. 1-11, 2000.
AQ	S. Harish et al., "Transcriptional activation by hepatocyte nuclear factor-4 in a cell-free system derived from rat liver nucleic", Nucleic Acids Res., Vol. 29, No. 5, pp.1047-1053, 2001.

EXAMINER

DATE CONSIDERED